Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors

OBJECTIVE: Multiple myeloma patients who are relapsed or refractory to both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have been reported to have poor outcomes. Bendamustine has been reported to have an antitumor effect in newly diagnosed as well as relapsed/refractory multiple m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yalnız, Fevzi Fırat, Akkoç, Nihan, Salihoğlu, Ayşe, Ar, M. Cem, Öngören, Şeniz, Eşkazan, A. Emre, Soysal, Teoman, Aydın, Yıldız
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544042/
https://www.ncbi.nlm.nih.gov/pubmed/28270368
http://dx.doi.org/10.4274/tjh.2016.0397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544042/
https://www.ncbi.nlm.nih.gov/pubmed/28270368
http://dx.doi.org/10.4274/tjh.2016.0397

Ejemplares similares